Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,480.73 63.20 0.44%
TOPIX 1,169.46 2.87 0.25%
HANG SENG 22,760.24 64.23 0.28%

Smith & Nephew launches natural-motion knee replacement at AAOS annual meeting



Smith & Nephew launches natural-motion knee replacement at AAOS annual meeting

PR Newswire

LONDON, March 19, 2013

LONDON, March 19, 2013 /PRNewswire/ -- Smith & Nephew (LSE:SN NYSE:SNN), the
global medical technology business, announces the showcasing of the JOURNEY™
II Bi-Cruciate Stabilized (BCS) knee replacement at this year's American
Academy of Orthopaedic Surgeons (AAOS) meeting in Chicago, March 19-23.

To view the multimedia assets associated with this release, please click
http://www.prnewswire.com/news-releases/smith--nephew-launches-natural-motion-knee-replacement-at-aaos-annual-meeting-198899181.html

The JOURNEY II BCS knee sets a new standard in knee implant performance by
restoring more normal motion.  This is achieved through the reproduction of
both the shapes of the joint's hard surfaces and the normal force behavior of
the soft tissues, such as ligament and muscle firing patterns. As a result,
the soft tissue's readjustment to new shapes and forces after surgery is
minimized, helping to return the patient's stride to its natural rhythm.

"The JOURNEY II BCS knee takes knee performance beyond the current standards
for fit and alignment and gives patients the complex motion, strength and
stability of a human knee," said Gaurav Agarwal, President of Smith & Nephew's
joint reconstruction business.  "You don't have to ask patients if it feels
like a normal knee—you can see it in their gait and in their post-op x-rays. 
We redefined knee implant function when we launched the original JOURNEY knee
in 2005, and with JOURNEY II BCS we have again outpaced traditional knee
replacement technology."

This latest innovation is the result of intense research and design, and the
development of new PHYSIOLOGICAL MATCHING™ Technology. Using its LifeMOD™
human simulation software, Smith & Nephew engineers were able to conduct
proprietary analysis of the bone, ligament and muscle forces that impact the
knee, and then account for those forces within the design of an implant that
restores anatomic shapes and normal motion.

"Unlike implants that create unnatural motion with a symmetric, circular
design, or with a rotating platform, the JOURNEY II BCS knee accommodates the
swing-and-rotate of the knee with the same engineering principles the body
naturally uses," explains Steven Haas, MD, Chief of the Knee Service at
Hospital for Special Surgery in New York City.  "As a result, the muscles and
ligaments around the new joint don't have to work harder because the implant's
natural shape and resulting motion allow these soft tissues to move in
familiar ways. This leads to higher patient satisfaction scores, more
mechanical efficiency of the muscle, and a more natural feeling while walking
or bending in the months after their procedure."

The JOURNEY II BCS knee is made from Smith & Nephew's VERILAST™ Technology.
 The combination of two wear reducing materials – proprietary OXINIUM™ alloy
and a highly cross-linked plastic liner, VERILAST Technology generates a
significant reduction in implant wear compared to traditional bearing couples
on the market.  On traditional plastic liners, OXINIUM material is 4,900 times
more abrasion resistant than cobalt chrome and reduces knee replacement wear
on traditional liners by up to 85-percent compared to cobalt chrome
components.[i]

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 10,500 employees and a presence in more than 90 countries.
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member
of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit:  www.smith-nephew.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors.

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

Trademark of Smith & Nephew.  Registered US Patent and Trademark Office.

[i] G. Hunter and M. Long, "Abrasive wear of oxidized Zr-2.5Nb, CoCrMo, and
Ti-6Al-4V against bone cement", 6th World Biomaterials Cong. Trans., Society
For Biomaterials, Minneapolis, MN, 2000, p. 835.

SOURCE Smith & Nephew

Website: http://www.smith-nephew.com
Contact: Media, Andrew Burns, Smith & Nephew, +1-901-399-5739,
Andrew.Burns@smith-nephew.com; Investor/Analyst, Phil Cowdy, Smith & Nephew,
44 (0)20 7401 7646, Phil.Cowdy@smith-nephew.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement